Consistent Outcomes With Canagliflozin in Patients With Type 2 Diabetes Across Geographic Regions

Newer researches in the field of Diabetes are bringing up newer molecules, one such introduced in the last decade is called SGLT2 Inhibitors – an Important one in this group is Canagliflozin. Recently conducted multinational Trial with 10,000 subjects showed this is useful across the continents, all adults, all races and both sexes.

For the full report please click here – ADA 2018 CANVAS Program outcomes by geographic region poster_JGL-63475

Speak Your Mind

*